Skip to main content
Medical information Clinical review pending

Genetic Testing

AHDC1 Gene Mental Retardation Autosomal Dominant Type 25 Genetic Test

Genetic test using Next-Generation Sequencing (NGS) to analyze the AHDC1 gene, aiding in the diagnosis of specific neurological disorders associated with cognitive impairment and developmental delays.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question
Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample
Blood sample (usually collected in an EDTA tube). Confirm with the laboratory before booking.
Results
Confirm with the laboratory before booking.
Preparation
A Genetic Counseling session is required prior to testing to discuss the implications and draw a family pedigree chart.
Test priceKSh 40,000

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the AHDC1 Gene Mental Retardation Autosomal Dominant Type 25 Genetic Test test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

  • Insurer or scheme name & policy / member number
  • A clinician's request / prescription for the test
  • Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

+254

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

01

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

  • ✓Individuals with symptoms suggestive of AHDC1-related disorder
  • ✓Developmental delay or intellectual disability of unknown cause
  • ✓Family history of AHDC1-related disorder
  • ✓Genetic counseling for families with neurological disorders
  • ✓Confirmation of suspected diagnosis based on clinical features
02

In plain language

What this test helps you understand

This test helps identify mutations in the AHDC1 gene, which can confirm a diagnosis of AHDC1-related mental retardation autosomal dominant type 25. This information can aid in understanding the cause of neurological symptoms, guiding management, and informing family planning.
The AHDC1 Gene Mental Retardation Autosomal Dominant Type 25 NGS Genetic DNA Test is a diagnostic tool used to identify genetic causes of certain neurological disorders. It utilizes Next-Generation Sequencing (NGS) technology to analyze the AHDC1 gene, which has been linked to mental retardation and other cognitive disabilities. Understanding the genetic basis of these conditions can help guide management, early intervention, and family planning.

This test specifically looks for mutations within the AHDC1 gene. By examining a patient's DNA, it can identify genetic alterations that may contribute to neurological symptoms. This information can assist healthcare providers in diagnosis and treatment planning.

Individuals experiencing symptoms of cognitive impairment or developmental delays may be candidates for this test. Factors suggesting consideration include a family history of neurological disorders or observed developmental delays in children. Consultation with a neurologist or genetic counselor is recommended to determine if this test is appropriate.

Taking this test can provide valuable insights into the genetic factors influencing cognitive function. It can support informed decisions regarding family planning and management strategies. Results may also guide potential treatment options and interventions. Discussing the results with a healthcare professional is crucial for proper interpretation and understanding the next steps.
03

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →
04

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

1

Speak with us

We check the test and answer your questions before collection.

2

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

3

Understand your report

A counselor helps you understand the result and the next steps.

05

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →
PreparationA Genetic Counseling session is required prior to testing to discuss the implications and draw a family pedigree chart.
SampleBlood sample (usually collected in an EDTA tube). Confirm with the laboratory before booking.
MethodologyNext-Generation Sequencing (NGS) is used to analyze the AHDC1 gene for specific mutations.
PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.
This test analyzes only the AHDC1 gene. It will not detect mutations in other genes that may cause similar symptoms. A negative result does not completely rule out a genetic cause for the condition. The test may not detect all possible types of mutations within the AHDC1 gene.
06

Read your report

What common result terms mean

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.
NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.
VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.
07

Questions people ask

Frequently asked questions

The AHDC1 gene provides instructions for making a protein involved in brain development and function. Mutations in this gene are associated with certain neurological disorders.
Individuals with developmental delays, intellectual disability, or specific neurological symptoms, especially if there is a family history, may be considered for this test after consultation with a doctor or genetic counselor.
A positive result indicates that a mutation in the AHDC1 gene was found. This may help explain the patient's symptoms, but further discussion with a healthcare provider is needed to understand the implications.
A negative result means no mutations were detected in the AHDC1 gene within the scope of the test. It does not rule out other genetic causes for the symptoms.
Yes, a genetic counseling session is required before testing to discuss the test's purpose, benefits, limitations, and potential results.
The sample is typically a blood draw. Confirm specific collection requirements with the laboratory.
08

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships
09

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

  • ACMG/AMP technical standards for sequence variant interpretation
  • ClinGen curation and gene–disease validity frameworks where applicable
  • LOINC-coded reporting for interoperable results
  • ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

  • Last updated: September 27, 2026
  • Medical review: not yet completed
  • Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →
Chat on WhatsApp